Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 1/20 | 0.57 |
| ▸ | ADRB2 | P07550 | 8/20 | 0.49 |
| ▸ | ADRB1 | P08588 | 8/20 | 0.49 |
| ▸ | ADRB3 | P13945 | 6/20 | 0.49 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.48 |
| ▸ | TRIM24 | O15164 | 5/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | XIAP | P98170 | 1/20 | 0.42 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17545353 | 0.90 | ACLY (0.69) | ACLYADRB2ADRB1ADRB3P2RY4 | |
| SCHEMBL19219772 | 0.84 | ACLY (0.51) | ACLYP2RY4TRIM24TP53XIAP | |
| SCHEMBL19219770 | 0.83 | ACLY (0.49) | ACLYP2RY4TRIM24NPC1TP53 | |
| SCHEMBL19219768 | 0.78 | ACLY (0.44) | ACLYP2RY4XIAPBIRC2 | |
| SCHEMBL19219764 | 0.78 | ACLY (0.44) | ACLYP2RY4TRIM24NPC1TP53 | |
| SCHEMBL19219767 | 0.78 | GAA (0.59) | ACLYTP53 | |
| SCHEMBL19219761 | 0.76 | XIAP (0.45) | ACLYP2RY4TP53XIAPBIRC2 | |
| SCHEMBL19219755 | 0.75 | NPSR1 (0.52) | ACLYTP53XIAPBIRC2 | |
| SCHEMBL19219754 | 0.74 | XIAP (0.44) | ACLYTP53XIAPBIRC2 | |
| SCHEMBL17545354 | 0.74 | ACLY (0.61) | ACLYP2RY4TRIM24NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170226090-A1 | INDOLINE SULFONAMIDE INHIBITORS OF DAPE AND NDM-1 AND USE OF THE SAME | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2017-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226090-A1 | INDOLINE SULFONAMIDE INHIBITORS OF DAPE AND NDM-1 AND USE OF THE SAME | INMT, MGAM, NNMT | ACLY 1668/4885ADRB2 3565/4885ADRB1 3123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.